AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graybill, J. R.
Right arrow Articles by Rinaldi, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graybill, J. R.
Right arrow Articles by Rinaldi, M. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1998, p. 151-153, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Treatment of Histoplasmosis with MK-991 (L-743,872)

John R. Graybill,1,2,* Laura K. Najvar,1 Eleanor M. Montalbo,1 Francesco J. Barchiesi,1 Michael F. Luther,2 and Michael G. Rinaldi1,2

The University of Texas Health Science Center at San Antonio,1 and South Texas Veterans Health Care System, Audie Murphy Division,2 San Antonio, Texas 78284

Received 7 July 1997/Returned for modification 12 August 1997/Accepted 16 October 1997

BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

* Corresponding author. Mailing address: South Texas Veterans Health Care System, Audie Murphy Division (111F), 7400 Merton Minter Blvd., San Antonio, TX 78284. Phone: (210) 617-5111. Fax: (210) 614-6197. E-mail: GRAYBILL{at}UTHSCSA.EDU.

Antimicrobial Agents and Chemotherapy, January 1998, p. 151-153, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.